CAJ | 학술논문

目的：观察化疗交替靶向药物治疗对EGFR突变阳性的晚期非小细胞肺癌患者PFS及OS的影响。方法选取100例EGFR突变阳性的晚期NSCLC患者作为研究对象，将患者分为2组，A组为吉西他滨＋顺铂／卡铂化疗交替吉非替尼组，B组为单用吉非替尼组。比较患者治疗过程中的耐受情况、不良反应的发生率和总缓解率（ ORR）；对比A、B组患者的肿瘤无进展生存期（ PFS）、总生存期（ OS）和患者生活质量评分（ QoL）。结果2组患者的不良反应发生率无统计学差异（P＞0．05），治疗期间A组5例患者因无法耐受不良反应而退出，B组4例患者退出。 A组患者ORR为68．89％，B组ORR为47．86％，差异具有统计学意义（P＜0．05）。 A组患者的PFS、OS和QoL高于B组，差异具有统计学意义（ P＜0．05）。结论化疗交替靶向药物在晚期EGFR突变阳性的NSCLC的治疗中具有显著的临床疗效，值得在临床上进行推广和应用。
목적：관찰화료교체파향약물치료대EGFR돌변양성적만기비소세포폐암환자PFS급OS적영향。방법선취100례EGFR돌변양성적만기NSCLC환자작위연구대상，장환자분위2조，A조위길서타빈＋순박／잡박화료교체길비체니조，B조위단용길비체니조。비교환자치료과정중적내수정황、불량반응적발생솔화총완해솔（ ORR）；대비A、B조환자적종류무진전생존기（ PFS）、총생존기（ OS）화환자생활질량평분（ QoL）。결과2조환자적불량반응발생솔무통계학차이（P＞0．05），치료기간A조5례환자인무법내수불량반응이퇴출，B조4례환자퇴출。 A조환자ORR위68．89％，B조ORR위47．86％，차이구유통계학의의（P＜0．05）。 A조환자적PFS、OS화QoL고우B조，차이구유통계학의의（ P＜0．05）。결론화료교체파향약물재만기EGFR돌변양성적NSCLC적치료중구유현저적림상료효，치득재림상상진행추엄화응용。
Objective To observe the effect of chemotherapy alternately targeted drugs on progression free survival ( PFS) and overall survival( OS) in EGFR mutation positive patients with advanced non-small cell lung cancer ( NSCLC) .Meth-ods 100 cases of EGFR mutation positive patients with advanced NSCLC were chosen as the research object,and were divided into 2 groups,group A received gemcitabine +cisplatin /carboplatin chemotherapy alternated with gefitinib, and group B re-ceived the single use of gefitinib.Tolerance,adverse reaction rates and total remission rates( ORR) during the treatment process were compared;PFS,OS and quality of life score( QoL) were contrasted between group A and B.Results The rates of adverse reactions of the 2 groups showed no statistical difference(P>0.05).During the treatment,due to the severity of adverse reaction 5 patients in group A quitted,and 4 in group B quitted;ORR of group A was 68.89%,and that of group B was 47.86%,there had significant difference(P<0.05).PFS,OS and QoL of patients in group A were higher than those of group B,there had signif-icant difference(P<0.05).Conclusion Chemotherapy alternately targeted drugs for EGFR mutation positive patients with ad-vanced NSCLC has significant clinical efficacy,it is worthy of clinical promotion and application.